388 related articles for article (PubMed ID: 11838733)
1. Smoking as a risk factor for Graves' disease, toxic nodular goiter, and autoimmune hypothyroidism.
Vestergaard P; Rejnmark L; Weeke J; Hoeck HC; Nielsen HK; Rungby J; Laurberg P; Mosekilde L
Thyroid; 2002 Jan; 12(1):69-75. PubMed ID: 11838733
[TBL] [Abstract][Full Text] [Related]
2. Influence of smoking on Graves' disease with or without ophthalmopathy and nontoxic nodular goiter in Taiwan.
Chen YL; Chang TC; Chen CJ
J Formos Med Assoc; 1994 Jan; 93(1):40-4. PubMed ID: 7915579
[TBL] [Abstract][Full Text] [Related]
3. Smoking and risk of Graves' disease.
Prummel MF; Wiersinga WM
JAMA; 1993 Jan; 269(4):479-82. PubMed ID: 8419666
[TBL] [Abstract][Full Text] [Related]
4. Smoking and thyroid disorders--a meta-analysis.
Vestergaard P
Eur J Endocrinol; 2002 Feb; 146(2):153-61. PubMed ID: 11834423
[TBL] [Abstract][Full Text] [Related]
5. Quality-of-Life Impairments Persist Six Months After Treatment of Graves' Hyperthyroidism and Toxic Nodular Goiter: A Prospective Cohort Study.
Cramon P; Winther KH; Watt T; Bonnema SJ; Bjorner JB; Ekholm O; Groenvold M; Hegedüs L; Feldt-Rasmussen U; Rasmussen ÅK
Thyroid; 2016 Aug; 26(8):1010-8. PubMed ID: 27370744
[TBL] [Abstract][Full Text] [Related]
6. Transition of nodular toxic goiter to autoimmune hyperthyroidism triggered by 131I therapy.
Nygaard B; Faber J; Veje A; Hegedüs L; Hansen JM
Thyroid; 1999 May; 9(5):477-81. PubMed ID: 10365679
[TBL] [Abstract][Full Text] [Related]
7. Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism.
Franklyn JA; Daykin J; Holder R; Sheppard MC
QJM; 1995 Mar; 88(3):175-80. PubMed ID: 7767667
[TBL] [Abstract][Full Text] [Related]
8. Increased Cardiovascular Mortality and Morbidity in Patients Treated for Toxic Nodular Goiter Compared to Graves' Disease and Nontoxic Goiter.
Giesecke P; Rosenqvist M; Frykman V; Friberg L; Wallin G; Höijer J; Lönn S; Törring O
Thyroid; 2017 Jul; 27(7):878-885. PubMed ID: 28471268
[TBL] [Abstract][Full Text] [Related]
9. Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements.
Berg GE; Michanek AM; Holmberg EC; Fink M
J Nucl Med; 1996 Feb; 37(2):228-32. PubMed ID: 8667049
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up study of radioiodine treatment of hyperthyroidism.
Metso S; Jaatinen P; Huhtala H; Luukkaala T; Oksala H; Salmi J
Clin Endocrinol (Oxf); 2004 Nov; 61(5):641-8. PubMed ID: 15521969
[TBL] [Abstract][Full Text] [Related]
11. Smoking and other lifestyle factors and the risk of Graves' hyperthyroidism.
Holm IA; Manson JE; Michels KB; Alexander EK; Willett WC; Utiger RD
Arch Intern Med; 2005 Jul; 165(14):1606-11. PubMed ID: 16043678
[TBL] [Abstract][Full Text] [Related]
12. Thyroid diseases after treatment of Hodgkin's disease.
Hancock SL; Cox RS; McDougall IR
N Engl J Med; 1991 Aug; 325(9):599-605. PubMed ID: 1861693
[TBL] [Abstract][Full Text] [Related]
13. Pattern, clinical presentations and management of thyroid diseases in national endocrine referral clinics, Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia.
Kebede D; Abay Z; Feleke Y
Ethiop Med J; 2012 Oct; 50(4):287-95. PubMed ID: 23930473
[TBL] [Abstract][Full Text] [Related]
14. Relevance of cause of hyperthyroidism in determining its management.
Veneman TF; Weymer M; Tjabbes T; van Haeften TW
Neth J Med; 1989 Dec; 35(5-6):303-8. PubMed ID: 2635287
[TBL] [Abstract][Full Text] [Related]
15. Graves' hyperthyroidism and moderate alcohol consumption: evidence for disease prevention.
Carlé A; Bülow Pedersen I; Knudsen N; Perrild H; Ovesen L; Rasmussen LB; Jørgensen T; Laurberg P
Clin Endocrinol (Oxf); 2013 Jul; 79(1):111-9. PubMed ID: 23170908
[TBL] [Abstract][Full Text] [Related]
16. [Radioiodine treatment of hyperthyroidism using a simplified dosimetric approach. Clinical results].
Giovanella L; De Palma D; Ceriani L; Vanoli P; Garancini S; Tordiglione M; Tarolo GL
Radiol Med; 2000 Dec; 100(6):480-3. PubMed ID: 11307510
[TBL] [Abstract][Full Text] [Related]
17. Radioiodine treatment of hyperthyroidism-prognostic factors for outcome.
Allahabadia A; Daykin J; Sheppard MC; Gough SC; Franklyn JA
J Clin Endocrinol Metab; 2001 Aug; 86(8):3611-7. PubMed ID: 11502786
[TBL] [Abstract][Full Text] [Related]
18. [Thyroid diseases in sub-Saharan Africa].
Sidibé el H
Sante; 2007; 17(1):33-9. PubMed ID: 17897900
[TBL] [Abstract][Full Text] [Related]
19. Hyperthyroidism due to Graves' disease and due to autonomous goiter.
Schicha H; Emrich D; Schreivogel I
J Endocrinol Invest; 1985 Oct; 8(5):399-407. PubMed ID: 3841136
[TBL] [Abstract][Full Text] [Related]
20. Decreased nerve growth factor levels in hyperthyroid Graves' ophthalmopathy highlighting the role of neuroprotective factor in autoimmune thyroid diseases.
Molnár I; Bokk A
Cytokine; 2006 Aug; 35(3-4):109-14. PubMed ID: 17008110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
